Surfactant preparations have been proven to improve clinical outcome of infants at risk for or
having respiratory distress syndrome (RDS). In clinical trials, ani mal-derived surfactant …

Type I and type II pneumocytes are two forms of epithelial cells found lining the alveoli in the
lungs. Type II pneumocytes exclusively secrete 'pulmonary surfactants,'a lipoprotein …

This review documents the evolution of surfactant therapy, beginning with observations of
surfactant deficiency in respiratory distress syndrome, the basis of exogenous surfactant …

A deficiency in alveolar surfactant due to immaturity of alveolar type II epithelial cells causes
respiratory distress syndrome (RDS). In contrast to animals, the fetal maturation of surfactant …

Exogenous surfactant therapy has been part of the routine care of preterm neonates with
respiratory distress syndrome (RDS) since the beginning of the 1990s. Discoveries that led …

Understanding surfactant composition, function, and therapeutic usefulness has increased
exponentially over the last 40 years. This article reviews the history and current …

Discovery of lung surfactant deficiency as a main cause of neonatal respiratory distress
syndrome (NRDS) has influenced a steep increase in lung surfactant research. Although this …

Exogenous surfactant therapy offers great promise for reducing the severity, morbidity, and
early mortality attributable to the respiratory distress syndrome (RDS). The RDS remains the …

Acute respiratory distress syndrome (ARDS) was first described about 30 years ago. Modern
definitions and statements have recently been proposed to describe ARDS accurately, but …

Since Fujiwara et al.[1] published the first promising results of surfactant replacement in
neonatal respiratory distress syndrome (RDS), there has been rapidly growing interest in the …